Literature DB >> 10722430

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

D L Paterson1, L Mulazimoglu, J M Casellas, W C Ko, H Goossens, A Von Gottberg, S Mohapatra, G M Trenholme, K P Klugman, J G McCormack, V L Yu.   

Abstract

A prospective study of Klebsiella pneumoniae bacteremia was performed in 12 hospitals in 7 countries. Of 452 episodes of bacteremia, 25 (5.5%) were caused by K. pneumoniae that was resistant in vitro to ciprofloxacin. Extended-spectrum beta-lactamase (ESBL) production was detected in 15 (60%) of 25 ciprofloxacin-resistant isolates, compared with 68 (16%) of 427 ciprofloxacin-susceptible strains (P=.0001). Multivariate analysis revealed that risk factors for ciprofloxacin resistance in K. pneumoniae included prior receipt of a quinolone (P=.0065) and an ESBL-producing strain (P=.012). In all, 18% of ESBL-producing isolates were also ciprofloxacin-resistant. Pulsed-field gel electrophoresis showed that 11 of the 15 ciprofloxacin-resistant ESBL-producing strains belonged to just 4 genotypes, suggesting that patient-to-patient transmission of such strains occurred. The close relationship between ESBL production and ciprofloxacin resistance is particularly worrisome because the first reported instance of plasmid-mediated ciprofloxacin resistance has been in an isolate of K. pneumoniae also possessing an ESBL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722430     DOI: 10.1086/313719

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  85 in total

1.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Recent developments in beta lactamases and extended spectrum beta lactamases.

Authors:  Joumana N Samaha-Kfoury; George F Araj
Journal:  BMJ       Date:  2003-11-22

4.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

5.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

6.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

7.  [Epidemiology of and preventive measures for multiresistant pathogens].

Authors:  E-B Kruse; M Dettenkofer
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

8.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 9.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

10.  Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.

Authors:  Hyunjoo Pai; Mi-Ran Seo; Tae Yeal Choi
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.